Earlier this month, COMPASS Pathways welcomed a White House Executive Order aimed at accelerating treatments for serious mental illness, as it reported two positive phase 3 trials of its COMP360 ...

Compass Pathways stock rallies as Trump’s new executive order aims at accelerating approval and research of psychedelic ...

Donald Trump's order on psychedelic drugs sent shares of companies in the space surging. RFK Jr and Joe Rogan were present at ...

Compass Pathways may be the first to benefit from an accelerated approval process.

COMPASS Pathways PLC CMPS shares are soaring on Monday after President Donald Trump issued an executive order directing ...

COMPASS Pathways (CMPS) stock jumped 25% after Trump's executive order on psychedelic research. Positive Phase 3 data boosts ...

Over the weekend, President Donald Trump fast-tracked the approval process for psychedelic treatments for mental illnesses.

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

Shares of several pharmaceutical companies were higher after President Trump signed an executive order aimed at accelerating research, development and access to psychedelic medicines for the treatment ...

AtaiBeckley and Compass Pathways are two drugmakers developing psychedelic treatments for depression.

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today an invitation for U.S. based ...

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, welcomes the White House Executive Order on accelerating medical ...